Fundraising Fox

Maxwell Biosciences

Austin, US · Delaware corporation · 4 known investors

maxwellbiosciences.com ↗

Maxwell Biosciences is a preclinical-stage biotechnology company developing its CLAROMER platform, which produces peptoid-based (peptidomimetic) small-molecule anti-infectives that mimic innate immune peptides to target bacteria, fungi, viruses, and biofilms. Its lead candidate MXB-22,510, delivered as a nasal spray, targets broad-spectrum and drug-resistant infections, with human trials planned for 2026.

AI & Machine LearningBiotechLongevity

Founders & leadership

JM
Joshua McClureExecutive Officer, Director, Promoter
KM
Kate McKinleyDirector
PT
Praveen TyleDirector
BR
Barbara R HolcombDirector
AB
Annelise BarronDirector

Investors · 4

Capital FactoryAustin
Das & Co.New York
Keiretsu ForumSan Francisco · $250K – $2M
LoftyInc CapitalHouston

Reported raises · per SEC filings

Form D private placements
▶$25MofferedJul 2023 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joshua McClureExecutive Officer, Director, Promoter
  • Kate McKinleyDirector
  • Praveen TyleDirector
  • Barbara R HolcombDirector
  • Annelise BarronDirector
Offering amount
$25M
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.9MraisedApr 2022 · 96 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Praveen TyleDirector
  • Annelise BarronDirector
  • Theodore MoskovitzDirector
  • Christopher JohnsDirector
  • Joshua McClureExecutive Officer, Director
Offering amount
$14.8M
Amount sold
$10.9M
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.